Centauri Therapeutics, a biotech company based in Cheshire’s Alderley Park, has secured a £30m Series A funding round to support the completion of clinical studies for its antimicrobial treatments. The drug discovery company, which develops immunotherapy treatments, is working towards the completion of Phase I clinical studies for CTX-187, its lead clinical candiate in the […] The post Cheshire-based biotech scores £30m Series A round appeared first on UKTN .